Compugen Ltd. Share Price Deutsche Boerse AG
Equities
CW9
IL0010852080
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.705 EUR | -66.24% |
|
-9.82% | 0.00% |
Sales 2024 * | 37.04M 33.87M 3.09B | Sales 2025 * | 41.12M 37.6M 3.43B | Capitalization | 167M 153M 13.98B |
---|---|---|---|---|---|
Net income 2024 * | -4M -3.66M -334M | Net income 2025 * | -1M -914K -83.51M | EV / Sales 2024 * | 4.52 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.07 x |
P/E ratio 2024 * |
-37.4
x | P/E ratio 2025 * |
374
x | Employees | 68 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.62% |
Latest transcript on Compugen Ltd.
Managers | Title | Age | Since |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01/02/01 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01/22/01 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 02/17/02 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11/18/11 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11/18/11 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 47.96B | |
+0.69% | 42.45B | |
+44.59% | 41.47B | |
+30.52% | 31.6B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B |
- Stock Market
- Equities
- CGEN Stock
- CW9 Stock